Subcutaneous Furosemide: A Novel to Euvolemia.
Journal
Cardiology in review
ISSN: 1538-4683
Titre abrégé: Cardiol Rev
Pays: United States
ID NLM: 9304686
Informations de publication
Date de publication:
23 Mar 2024
23 Mar 2024
Historique:
medline:
23
3
2024
pubmed:
23
3
2024
entrez:
23
3
2024
Statut:
aheadofprint
Résumé
Furoscix, a subcutaneous pH-neutral formulation of furosemide, obtained US Food and Drug Administration approval in October 2022 for adult patients with New York Heart Association class II and class III chronic heart failure. This approval marks an anticipated potential shift in the traditional management of decongestive therapy in chronic heart failure patients from the confines of the hospital to more accessible outpatient or home-based care. In this review, we will summarize existing evidence regarding the use of subcutaneous furosemide in comparison to both oral and intravenous formulations, highlighting the demonstrable benefits of its application in both outpatient and inpatient settings, and also discuss several factors that may limit its use.
Identifiants
pubmed: 38520337
doi: 10.1097/CRD.0000000000000689
pii: 00045415-990000000-00236
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: The authors declare no conflict of interest.
Références
Bozkurt B, Coats AJS, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and writing committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, cardiac society of Australia and New Zealand, and Chinese heart failure association. Eur J Heart Fail. 2021;23:352–380.
Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;2:CD003838.
Colombo PC, Doran AC, Onat D, et al. Venous congestion, endothelial and neurohormonal activation in acute decompensated heart failure: cause or effect? Curr Heart Fail Rep. 2015;12:215–222.
CardioMEMS Inc. CardioMEMS HF system, PA sensor and delivery system: User’s manual. 2014, May. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf10/p100045d.pdf. Accessed December 6, 2023.
Ayyadurai P, Alkhawam H, Saad M, et al. An update on the CardioMEMS pulmonary artery pressure sensor. Ther Adv Cardiovasc Dis. 2019;13:1753944719826826.
Abraham WT, Adamson PB, Bourge RC, et al.; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 20119766;377:658–666.
James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789–1858.
Heidenreich PA, Albert NM, Allen LA, et al.; American Heart Association Advocacy Coordinating Committee. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–619.
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association [published correction appears in Circulation. 2022 Sep 6;146(10):e141]. Circulation. 2022;145:e153–e639.
Fonarow GC; ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4:S21–S30.
Halatchev IG, Wu WC, Heidenreich PA, et al. Inpatient versus outpatient intravenous diuresis for the acute exacerbation of chronic heart failure. Int J Cardiol Heart Vasc. 2021;36:100860.
Afari ME, Aoun J, Khare S, et al. Subcutaneous furosemide for the treatment of heart failure: a state-of-the art review. Heart Fail Rev. 2019;24:309–313.
Casu G, Merella P. Diuretic therapy in heart failure - current approaches. Eur Cardiol. 2015;10:42–47.
Girerd N, Mewton N, Tartière JM, et al.; a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology. Practical outpatient management of worsening chronic heart failure. Eur J Heart Fail. 2022;24:750–761.
Carone L, Oxberry SG, Twycross R, et al. Furosemide. J Pain Symptom Manage. 2016;52:144–150.
Verma AK, da Silva JH, Kuhl DR. Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study. Ann Pharmacother. 2004;38:544–549.
Sica DA, Muntendam P, Myers RL, et al. Subcutaneous furosemide in heart failure: pharmacokinetic characteristics of a newly buffered solution. JACC Basic Transl Sci. 2018;3:25–34.
Zacharias H, Raw J, Nunn A, et al. Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure? Palliat Med. 2011;25:658–663.
Gilotra NA, Princewill O, Marino B, et al. Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail. 2018;6:65–70.
Konstam MA, Udelson JE. Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study (AT HOME-HF). National Library of Medicine. 2023; NCT04593823.
Adrian Hernandez MD, Eugene Braunwald MD. Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot (SUBQ-Pilot). National Library of Medicine. 2019; NCT02877095.
Greene SJ, Mentz RJ, Felker GM. Outpatient worsening heart failure as a target for therapy: a review. JAMA Cardiol. 2018;3:252–259.
Fresenius Kabi. Furoscix. Fresenius Kabi USA. Available at: https://www.furosciz.com/hcp/?gclid=Cj0KCQjw0bunBhD9ARIsAAZI0E3pZd1fdT-CPg-tv_J4mvvzq9CtX43zcQPooSYL8ab2nRoj7TbGW5gaArXJEALw_wcB&gclsrc=aw.ds. Accessed 8/24/23.
Dahiya G, Bensimhon D, Goodwin MM, et al. From oral to subcutaneous furosemide: the road to novel opportunities to manage congestion. Struct Heart. 2022;6:100076.
Birch F, Boam E, Parsons S, et al. Subcutaneous furosemide in advanced heart failure: service improvement project. BMJ Support Palliat Care. 2023;13:112–116.
Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int. 2014;2014:937398.
BiotechValley Insights: scPharmaceuticals: Furoscix Launch And Market Access; A Promising Outlook [Seeking Alpha web site]. March 28, 2023. Available at: https://seekingalpha.com/article/4590579-scpharmaceuticals-furoscix-launch-and-market-access-a-promising-outlook. Accessed December 8, 2023.